(Q45889419)

17 December 2017

review article

1 reference

title

Immunotherapy and experimental approaches for metastatic melanoma (English)

1 reference

17 December 2017

1 reference

1 reference

M B Atkins

1

1 reference

17 December 2017

publication date

1 August 1998

1 reference

17 December 2017

Hematology / Oncology Clinics of North America

published in

1 reference

17 December 2017

volume

12

1 reference

17 December 2017

issue

4

1 reference

17 December 2017

page(s)

877-902, viii

1 reference

17 December 2017

Malignant melanoma: prognostic indicators

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Class II histocompatibility antigen expression in human melanocytes transformed by Harvey murine sarcoma virus (Ha-MSV) and Kirsten MSV retroviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Interferons in melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

The treatment of metastatic melanoma with chemotherapy and biologics

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Clinical Activity of a Polyvalent Melanoma Antigen Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Isolation perfusion for malignant melanoma of the extremity: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-016

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Pilot trial of murine monoclonal antibodies in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Interleukin-2-Based Immunotherapy and Chemoimmunotherapy in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Interferon alpha-2a and dacarbazine in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Active-specific immunotherapy for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Re: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

FLT3 ligand induces the generation of functionally active dendritic cells in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970029-0

7 January 2021

10.1016/S0889-8588(05)70029-0

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017